Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) Non Operating Income (2016 - 2025)

Historic Non Operating Income for BioCorRx (BICX) over the last 12 years, with Q3 2025 value amounting to $1.1 million.

  • BioCorRx's Non Operating Income rose 67505.1% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 96993.18%. This contributed to the annual value of -$89597.0 for FY2024, which is 61772.22% down from last year.
  • As of Q3 2025, BioCorRx's Non Operating Income stood at $1.1 million, which was up 67505.1% from $36644.0 recorded in Q2 2025.
  • Over the past 5 years, BioCorRx's Non Operating Income peaked at $1.1 million during Q3 2025, and registered a low of -$268771.0 during Q1 2024.
  • Over the past 5 years, BioCorRx's median Non Operating Income value was $45729.0 (recorded in 2023), while the average stood at $95171.2.
  • As far as peak fluctuations go, BioCorRx's Non Operating Income soared by 380709.72% in 2022, and later tumbled by 74106.31% in 2023.
  • Over the past 5 years, BioCorRx's Non Operating Income (Quarter) stood at $131403.0 in 2021, then plummeted by 82.63% to $22821.0 in 2022, then tumbled by 741.06% to -$146297.0 in 2023, then increased by 29.67% to -$102893.0 in 2024, then skyrocketed by 1205.11% to $1.1 million in 2025.
  • Its Non Operating Income stands at $1.1 million for Q3 2025, versus $36644.0 for Q2 2025 and $86182.0 for Q1 2025.